View Financial HealthDOD Biotech 配当と自社株買い配当金 基準チェック /06DOD Biotech配当を支払う会社であり、現在の利回りは3.05%です。主要情報3.0%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長-12.0%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向184%最近の配当と自社株買いの更新お知らせ • Feb 27+ 1 more updateDOD Biotech Public Company Limited announces Annual dividend, payable on May 05, 2026DOD Biotech Public Company Limited announced Annual dividend of THB 0.0500 per share payable on May 05, 2026, ex-date on March 13, 2026 and record date on March 16, 2026.すべての更新を表示Recent updatesお知らせ • Feb 27+ 1 more updateDOD Biotech Public Company Limited announces Annual dividend, payable on May 05, 2026DOD Biotech Public Company Limited announced Annual dividend of THB 0.0500 per share payable on May 05, 2026, ex-date on March 13, 2026 and record date on March 16, 2026.お知らせ • Feb 20DOD Biotech Public Company Limited, Annual General Meeting, Apr 28, 2025DOD Biotech Public Company Limited, Annual General Meeting, Apr 28, 2025, at 14:00 SE Asia Standard Time. Location: arrange a meeting in the format of an, Thailandお知らせ • Aug 19DOD Biotech Public Company Limited Appoints Porntep Siriwanarangsun as an Independent Director, Effective September 1, 2024DOD Biotech Public Company Limited announced the resolution of the Board of Directors Meeting No. 9/2567, held on August 16, 2024. The meeting resolved to appoint Dr. Porntep Siriwanarangsun as an Independent Director, replacing the resigning director, effective from September 1, 2024, onwards.お知らせ • Feb 23DOD Biotech Public Company Limited, Annual General Meeting, Apr 25, 2024DOD Biotech Public Company Limited, Annual General Meeting, Apr 25, 2024, at 14:00 Indian Standard Time. Location: Meeting Room no.1, DOD Biotech Public Company Limited, no. 111 Moo 2, Tha Chin Subdistrict, Mueang Samut Sakhon 74000 Samut Sakhon Thailand Agenda: To consider and acknowledge the Company's performance for the year 2023; to consider and approve the Company's audited the financial statements for the year ended December 31, 2023; to consider and acknowledge the omission of dividend payments for the year 2023; to consideration and approval of Transferring share premium to Offset accumulated Company Losses; and to discuss other matters.お知らせ • Jun 14DOD Biotech Public Company Limited has completed a Follow-on Equity Offering in the amount of THB 202.208528 million.DOD Biotech Public Company Limited has completed a Follow-on Equity Offering in the amount of THB 202.208528 million. Security Name: Shares Security Type: Common Stock Securities Offered: 25,552,382 Price\Range: THB 4 Security Name: Shares Security Type: Common Stock Securities Offered: 24,390,000 Price\Range: THB 4.1 Transaction Features: Rights Offering; Subsequent Direct Listingお知らせ • Nov 30+ 1 more updateDOD Biotech Public Company Limited Announces Executive ChangesDOD Biotech Public Company Limited at the Board of Directors' Meeting held on November 29, 2022 passed the resignation of Mr. Thanin Srisethi as Chief Executive Officer with effect from 30 November 2022 onward and Approved the appointment of Mr. Torlarp Chaiyachow as the Director, Acting Chief Executive Officer in place of Mr. Thanin Srisethi with effect from 1 December 2022 onwards.お知らせ • Feb 25+ 1 more updateDOD Biotech Public Company Limited Announces Executive ChangesDOD Biotech Public Company Limited acknowledged the resignation of M.L. Termsang Subphaso, she will be resigning from the positions of Chairman of the Board of Directors and Independence Director, and Mrs. Siew San Tan, she will be resigning from the Independence Director due to their personal business. Including to Mr. Wutichai Anantakul, he will be resigning from the Director and Chief Project Officer due to his other business. The resignations are effective from February 28, 2022 onwards. Approved the appointment of Mrs. Apaporn Kosolkul as a new Chairman of the Board, in order to fill in the casual vacancy created by M.L. Termsang Subphaso's resignation from the Board of Directors, with effect from March 1, 2022 onwards.お知らせ • Mar 17Rojukiss International Public Company Limited Enters Memorandum of Agreement with DOD Biotech Public Company LimitedRojukiss International Public Company Limited (KISS) has made a Memorandum of Agreement with DOD Biotech Public Company Limited (DOD); to hire DOD for conducting research and development including the production of Hemp-based skincare and food supplement products. This is to produce finished goods of said products and provide to a Joint Venture of KISS and O Shopping Co. Ltd. who shall sell and distribute hemp-based skincare and food supplement products. However, the development, production, and distribution of said product is in the process of waiting to be registered by the Food and Drug Administration (FDA). Any progress is made, shall be notified later.お知らせ • Mar 12+ 1 more updateDOD Biotech Public Company Limited Enters into MOU with 555 Shopping Company Limited to Develop Products Containing HempOn March 10, 2021, DOD Biotech Public Company Limited Company has entered into a memorandum of understanding with 555 Shopping Company Limited. This memorandum will be effected for 1 year. The company is the supplier of hemp seeds and the developer of the dietary supplements containing hemp as an ingredient. To sell to 555 Shopping Co. Ltd. and to buy hemp from the plantation of 555 Shopping Co. Ltd. in order to extract it as an important substance used in dietary supplements. In this regard, the production and distribution of products, mutually agreed upon, await the approval from the Food and Drug Administration. The further progress, will be informed once again.お知らせ • Mar 02DOD Biotech Public Company Limited, Annual General Meeting, Apr 29, 2021DOD Biotech Public Company Limited, Annual General Meeting, Apr 29, 2021, at 07:00 Coordinated Universal Time. Location: The Park Village Rama 2, 1/1-1/3 Soi Rama 2 Soi 56, Sameadam, Bangkhumtien Bangkok Thailand Agenda: To consider acknowledge the directors' report on the Company's performance for the year 2020; to consider approving the Company's audited the financial statements for the year ended December 31, 2020; to Consider and acknowledge the omission of dividend payments for the year 2020; to Consider and approve the allocation legal reserves and baht and the share premium to compensate for the accumulated loss of the company; to Consider and approve the appointment of the directors those retired by rotation to re-elect the aforementioned to be the Company's director for another term; to approve the fixing of the director's remuneration for the year 2021; to approve the appointment of the auditors and fixing the audit fee for the year 2021; and to consider other matter.決済の安定と成長配当データの取得安定した配当: DOD-Rは 10 年未満配当金を支払っており、この間、支払額は 変動性 が高かった。増加する配当: DOD-Rは8年間のみ配当金を支払っており、それ以降は支払額が減少しています。配当利回り対市場DOD Biotech 配当利回り対市場DOD-R 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (DOD-R)3.0%市場下位25% (TH)3.4%市場トップ25% (TH)7.5%業界平均 (Personal Products)5.4%アナリスト予想 (DOD-R) (最長3年)n/a注目すべき配当: DOD-Rの配当金 ( 3.05% ) はTH市場の配当金支払者の下位 25% ( 3.35% ) と比べると目立ったものではありません。高配当: DOD-Rの配当金 ( 3.05% ) はTH市場の配当金支払者の上位 25% ( 7.51% ) と比較すると低いです。株主への利益配当収益カバレッジ: DOD-Rは高い 配当性向 ( 184.4% ) のため、配当金の支払いは利益によって十分にカバーされていません。株主配当金キャッシュフローカバレッジ: DOD-Rは配当金を支払っていますが、同社にはフリーキャッシュフローがありません。高配当企業の発掘7D1Y7D1Y7D1YTH 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 15:45終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DOD Biotech Public Company Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Wilasinee BoonmasungsongGloblex Securities Co. Ltd.Hathaichanoke MoonwongPhillip Securities (Thailand) PCLApichat PoobunjirdkulTisco Securities Co. Ltd.1 その他のアナリストを表示
お知らせ • Feb 27+ 1 more updateDOD Biotech Public Company Limited announces Annual dividend, payable on May 05, 2026DOD Biotech Public Company Limited announced Annual dividend of THB 0.0500 per share payable on May 05, 2026, ex-date on March 13, 2026 and record date on March 16, 2026.
お知らせ • Feb 27+ 1 more updateDOD Biotech Public Company Limited announces Annual dividend, payable on May 05, 2026DOD Biotech Public Company Limited announced Annual dividend of THB 0.0500 per share payable on May 05, 2026, ex-date on March 13, 2026 and record date on March 16, 2026.
お知らせ • Feb 20DOD Biotech Public Company Limited, Annual General Meeting, Apr 28, 2025DOD Biotech Public Company Limited, Annual General Meeting, Apr 28, 2025, at 14:00 SE Asia Standard Time. Location: arrange a meeting in the format of an, Thailand
お知らせ • Aug 19DOD Biotech Public Company Limited Appoints Porntep Siriwanarangsun as an Independent Director, Effective September 1, 2024DOD Biotech Public Company Limited announced the resolution of the Board of Directors Meeting No. 9/2567, held on August 16, 2024. The meeting resolved to appoint Dr. Porntep Siriwanarangsun as an Independent Director, replacing the resigning director, effective from September 1, 2024, onwards.
お知らせ • Feb 23DOD Biotech Public Company Limited, Annual General Meeting, Apr 25, 2024DOD Biotech Public Company Limited, Annual General Meeting, Apr 25, 2024, at 14:00 Indian Standard Time. Location: Meeting Room no.1, DOD Biotech Public Company Limited, no. 111 Moo 2, Tha Chin Subdistrict, Mueang Samut Sakhon 74000 Samut Sakhon Thailand Agenda: To consider and acknowledge the Company's performance for the year 2023; to consider and approve the Company's audited the financial statements for the year ended December 31, 2023; to consider and acknowledge the omission of dividend payments for the year 2023; to consideration and approval of Transferring share premium to Offset accumulated Company Losses; and to discuss other matters.
お知らせ • Jun 14DOD Biotech Public Company Limited has completed a Follow-on Equity Offering in the amount of THB 202.208528 million.DOD Biotech Public Company Limited has completed a Follow-on Equity Offering in the amount of THB 202.208528 million. Security Name: Shares Security Type: Common Stock Securities Offered: 25,552,382 Price\Range: THB 4 Security Name: Shares Security Type: Common Stock Securities Offered: 24,390,000 Price\Range: THB 4.1 Transaction Features: Rights Offering; Subsequent Direct Listing
お知らせ • Nov 30+ 1 more updateDOD Biotech Public Company Limited Announces Executive ChangesDOD Biotech Public Company Limited at the Board of Directors' Meeting held on November 29, 2022 passed the resignation of Mr. Thanin Srisethi as Chief Executive Officer with effect from 30 November 2022 onward and Approved the appointment of Mr. Torlarp Chaiyachow as the Director, Acting Chief Executive Officer in place of Mr. Thanin Srisethi with effect from 1 December 2022 onwards.
お知らせ • Feb 25+ 1 more updateDOD Biotech Public Company Limited Announces Executive ChangesDOD Biotech Public Company Limited acknowledged the resignation of M.L. Termsang Subphaso, she will be resigning from the positions of Chairman of the Board of Directors and Independence Director, and Mrs. Siew San Tan, she will be resigning from the Independence Director due to their personal business. Including to Mr. Wutichai Anantakul, he will be resigning from the Director and Chief Project Officer due to his other business. The resignations are effective from February 28, 2022 onwards. Approved the appointment of Mrs. Apaporn Kosolkul as a new Chairman of the Board, in order to fill in the casual vacancy created by M.L. Termsang Subphaso's resignation from the Board of Directors, with effect from March 1, 2022 onwards.
お知らせ • Mar 17Rojukiss International Public Company Limited Enters Memorandum of Agreement with DOD Biotech Public Company LimitedRojukiss International Public Company Limited (KISS) has made a Memorandum of Agreement with DOD Biotech Public Company Limited (DOD); to hire DOD for conducting research and development including the production of Hemp-based skincare and food supplement products. This is to produce finished goods of said products and provide to a Joint Venture of KISS and O Shopping Co. Ltd. who shall sell and distribute hemp-based skincare and food supplement products. However, the development, production, and distribution of said product is in the process of waiting to be registered by the Food and Drug Administration (FDA). Any progress is made, shall be notified later.
お知らせ • Mar 12+ 1 more updateDOD Biotech Public Company Limited Enters into MOU with 555 Shopping Company Limited to Develop Products Containing HempOn March 10, 2021, DOD Biotech Public Company Limited Company has entered into a memorandum of understanding with 555 Shopping Company Limited. This memorandum will be effected for 1 year. The company is the supplier of hemp seeds and the developer of the dietary supplements containing hemp as an ingredient. To sell to 555 Shopping Co. Ltd. and to buy hemp from the plantation of 555 Shopping Co. Ltd. in order to extract it as an important substance used in dietary supplements. In this regard, the production and distribution of products, mutually agreed upon, await the approval from the Food and Drug Administration. The further progress, will be informed once again.
お知らせ • Mar 02DOD Biotech Public Company Limited, Annual General Meeting, Apr 29, 2021DOD Biotech Public Company Limited, Annual General Meeting, Apr 29, 2021, at 07:00 Coordinated Universal Time. Location: The Park Village Rama 2, 1/1-1/3 Soi Rama 2 Soi 56, Sameadam, Bangkhumtien Bangkok Thailand Agenda: To consider acknowledge the directors' report on the Company's performance for the year 2020; to consider approving the Company's audited the financial statements for the year ended December 31, 2020; to Consider and acknowledge the omission of dividend payments for the year 2020; to Consider and approve the allocation legal reserves and baht and the share premium to compensate for the accumulated loss of the company; to Consider and approve the appointment of the directors those retired by rotation to re-elect the aforementioned to be the Company's director for another term; to approve the fixing of the director's remuneration for the year 2021; to approve the appointment of the auditors and fixing the audit fee for the year 2021; and to consider other matter.